HMB supplement for head and neck cancer surgery
Part of Cancer clinical trials.
This trial tests whether taking HMB (a supplement that may help reduce inflammation) can improve recovery and outcomes in people with head and neck cancer who are scheduled for surgery to remove their tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with head and neck cancer.
- You are being treated at an outpatient clinic for head and neck cancer.
- Your doctor plans to do surgery to remove the tumor, and the goal is to cure the cancer.
- You do not have cancer of the face, skin, sinuses, or thyroid.
- You are not receiving chemotherapy or radiation before surgery, or only palliative care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special nutritional supplement can help maintain your nutrition and immune system during radiation therapy for head and neck cancer. It aims to reduce side effects and improve your overall health during treatment.
This trial tests whether adding an AHCC supplement to standard treatment can improve outcomes for people with HPV-positive head and neck cancer. It is for patients who have had surgery and have certain high-risk features, like positive margins or cancer spread to lymph nodes.
This trial tests whether adding postbiotics (beneficial bacteria byproducts) to the standard immunotherapy drug pembrolizumab can improve your immune system's response against advanced or metastatic head and neck squamous cell carcinoma.
This study tests whether patients recovering from head and neck cancer surgery can safely do supervised exercise exercises at home. The program aims to help you regain strength and function during your recovery.
This trial tests a new combination of immunotherapy (a drug that helps your immune system fight cancer) and a mitochondrial vaccine given before surgery for head and neck squamous cell carcinoma. The goal is to help reduce cancer recurrence and improve survival after surgery.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
Hear when a new Head and Neck Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.